Posted by Michael Wonder on 24 Apr 2024
Pembrolizumab in combination with gemcitabine and cisplatin for the first-line treatment of patients with advanced biliary tract cancer
24 April 2024 - NICE is unable to make a recommendation on the use of pembrolizumab (Keytruda) in combination with cisplatin and gemcitabine hydrochloride for first-line treatment of adults with advanced biliary tract cancer because Merck/MSD did not provide an evidence submission.
NICE will review this decision if Merck/MSD decides to make a submission.
